167 filings
Page 2 of 9
8-K
gbpov i0b7h
16 May 22
Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights
8:30am
8-K
4itlyzf1ptfy3
8 Apr 22
Entry into a Material Definitive Agreement
7:00pm
8-K
o3hv5hqrdf49 06x
1 Mar 22
Vyant Bio Issues Letter to Shareholders
8:30am
8-K
8abwe
24 Jan 22
Departure of Directors or Certain Officers
9:00am
8-K
9isv4za9qpwr9s
26 Oct 21
Other Events
8:00am
8-K
xh5cylev4zb 0pckx3d
16 Aug 21
Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates
4:01pm
8-K
yh4ap11tzhrfdoenqs
17 May 21
Vyant Bio Reports First Quarter 2021 Results and Provides Strategic Business Update
5:27pm
8-K
mp76mrgbb rf8yo
5 Apr 21
Report of Independent Registered Public Accounting Firm
5:12pm
8-K
oy1y60l
25 Mar 21
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX
9:17am
8-K
c9r0487i8
16 Mar 21
Other Events
7:02am
8-K
5ezdmfbn72bi8pxv
26 Feb 21
Entry into a Material Definitive Agreement
4:42pm
8-K
po35 g3siyxt4n4
16 Feb 21
Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
4:51pm
8-K
cfqixav1cpv
8 Feb 21
Entry into a Material Definitive Agreement
5:22pm
8-K
jc80 w2cpm
1 Feb 21
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market
5:24pm
8-K
tc3fosw 9m86
28 Jan 21
Other Events
3:42pm
8-K
uu762yt
8 Jan 21
Regulation FD Disclosure
4:30pm
8-K
084fcshjle jekr6jny6
7 Jan 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
89iwe prdjkett644l
2 Dec 20
Entry into a Material Definitive Agreement
9:54pm
8-K
r4y51mybaooon x3
2 Dec 20
Other Events
9:53pm
8-K
58zs1ppo6 uitdnch5k4
20 Nov 20
Entry into a Material Definitive Agreement
5:26pm